SCHEMBL844726

SCHEMBL844726

O=C(O)CC(=O)Oc1ccccc1C(=O)O

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 10/20 0.66
HSD17B10 Q99714 7/20 0.66
HPGD P15428 5/20 0.66
KMT2A Q03164 2/20 0.61
MEN1 O00255 1/20 0.61
RECQL P46063 1/20 0.61
ALDH1A1 P00352 8/20 0.59
ESR1 P03372 1/20 0.59
ITGB3 P05106 1/20 0.59
ITGA2B P08514 1/20 0.59
HMGB1 P09429 1/20 0.59
TSHR P16473 1/20 0.59
GGT1 P19440 1/20 0.59
PTGS1 P23219 1/20 0.59
PTGS2 P35354 1/20 0.59
BLM P54132 1/20 0.59
NAPRT Q6XQN6 1/20 0.59
TDP1 Q9NUW8 1/20 0.59
MAPT P10636 2/20 0.58
LMNA P02545 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL844727 0.92 KDM4E (0.70) KDM4EHSD17B10HPGDKMT2AMEN1
SCHEMBL11065761 0.86 KDM4E (0.67) KDM4EHSD17B10HPGDKMT2AMEN1
Diaspirin SCHEMBL40799 0.85 KDM4E (0.75) KDM4EHSD17B10HPGDKMT2AMEN1
Diaspirin SCHEMBL30735506 0.85 KDM4E (0.75) KDM4EHSD17B10HPGDKMT2AMEN1
SCHEMBL17787232 0.84 KDM4E (0.60) KDM4EHSD17B10HPGDKMT2AMEN1
SCHEMBL12446248 0.84 KDM4E (0.69) KDM4EHSD17B10HPGDKMT2AMEN1
SCHEMBL8436639 0.83 KDM4E (0.63) KDM4EHSD17B10HPGDKMT2AMEN1
SCHEMBL27145067 0.83 KDM4E (0.58) KDM4EHSD17B10HPGDKMT2AMEN1
SCHEMBL6129343 0.81 KDM4E (0.61) KDM4EHSD17B10HPGDKMT2AMEN1
Bromoaspirin SCHEMBL6691615 0.81 KDM4E (0.61) KDM4EHSD17B10HPGDKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160096788-A1 LIQUID CRYSTAL COMPOSITION HAVING A NEGATIVE LIQUID CRYSTAL MODE SAMSUNG DISPLAY CO., LTD. (KR) 2016-04-07 US claimed
US-9011734-B2 Ligand exchange thermochromic, (LETC), systems PLEOTINT, L.L.C. (US) 2015-04-21 US claimed
US-8018639-B2 Ligand exchange thermochromic, (LETC), systems PLEOTINT, L.L.C. (US) 2011-09-13 US claimed
US-20090283728-A1 LIGAND EXCHANGE THERMOCHROMIC, (LETC), SYSTEMS PLEOTINT, LLC (US) 2009-11-19 US claimed
EP-2082005-A1 LIGAND EXCHANGE THERMOCHROMIC, (LETC), SYSTEMS Pleotint, L.L.C. (US) 2009-07-29 EP claimed
US-20080100902-A1 LIGAND EXCHANGE THERMOCHROMIC, (LETC), SYSTEMS PLEOTINT, LLC (US) 2008-05-01 US claimed
WO-2008028128-A1 LIGAND EXCHANGE THERMOCHROMIC, (LETC), SYSTEMS PLEOTINT, L.L.C. (US) 2008-03-06 WO claimed
US-20160096788-A1 LIQUID CRYSTAL COMPOSITION HAVING A NEGATIVE LIQUID CRYSTAL MODE SAMSUNG DISPLAY CO., LTD. (KR) 2016-04-07 US disclosed
EP-2436750-A2 Ligand exchange thermochromic, (LETC), systems Pleotint, L.L.C. (US) 2012-04-04 EP disclosed
EP-2434000-A2 Ligand exchange thermochromic, (LETC), systems Pleotint, L.L.C. (US) 2012-03-28 EP disclosed
US-7253232-B2 Thermoplastic compositions with enhanced melt flow and compatibility CIBA SPECIALTY CHEMICALS CORP. (US) 2007-08-07 US disclosed
US-20070064195-A1 Stabilization of photochromic systems CIBA CORPORATION 2007-03-22 US disclosed
US-20050288435-A1 Thermoplastic compositions with enhanced melt flow and compatibility CIBA SPECIALTY CHEMICALS CORP. 2005-12-29 US disclosed
WO-1999026934-A1 TRISARYL-1,3,5-TRIAZINE ULTRAVIOLET LIGHT ABSORBERS CYTEC TECHNOLOGY CORP. (US) 1999-06-03 WO disclosed
WO-1999026935-A1 TRISARYL-1,3,5-TRIAZINE ULTRAVIOLET LIGHT ABSORBERS CYTEC TECHNOLOGY CORP. (US) 1999-06-03 WO disclosed
US-5788891-A Method for the forming of ceramic green parts CERAMTEC AG INNOVATIVE CERAMIC ENGINEERING (DE) 1998-08-04 US disclosed
US-5449776-A Polypropylene CIBA-GEIGY CORPORATION (US) 1995-09-12 US disclosed
EP-0605694-A1 PROCESS FOR PRODUCING CERAMIC GREEN BODIES. GAUCKLER LUDWIG J (CH) 1994-07-13 EP disclosed
WO-1994002429-A1 PROCESS FOR PRODUCING CERAMIC GREEN BODIES GAUCKLER LUDWIG J (CH) 1994-02-03 WO disclosed
US-4007158-A 9-AZA- 1,5-DIOXA-SPIRO (5,5) UNDECANES SANKYO COMPANY LIMITED (JA) 1977-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160096788-A1 LIQUID CRYSTAL COMPOSITION HAVING A NEGATIVE LIQUID CRYSTAL MODE SHBG, NCAPD2, RCC2 KDM4E 4394/4885HSD17B10 701/4885HPGD 4482/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.